


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents Washington, D.C. 20231 On

May 23, 2002  
By: Wendy Leaton

#11/B AQ  
PATENT  
Attorney Docket No.: 015280-368200US 1/2/02



JUN 05 2002 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Jay A. Berzofsky *et al.*

Application No.: 09/508,552

Filed: June 12, 2000

For: MUCOSAL CYTOTOXIC T  
LYMPHOCYTE RESPONSES

Examiner: J. Stucker

Art Unit: 1648

RECEIVED

JUN 12 2002

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO  
RESTRICTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Restriction Requirement dated January 8, 2002.

Please consider the following amendments and remarks prior to substantive examination of the present application.

IN THE SPECIFICATION:

Please amend the specification as set forth in detail herein below. An Appendix showing all changes to the specification is attached to this amendment as required by 37 CFR § 1.121(b).

Kindly replace the paragraph at page 5, line 34 to page 6, line 4, with the following paragraph:

B1  
Also provided within the invention are immunogenic compositions for inducing a protective mucosal CTL response in a subject which are adapted for intrarectal administration. The compositions comprise a purified soluble antigen formulated for intrarectal delivery to the rectum, colon, sigmoid colon, or distal colon. They may be formulated as a rectal enema, foam, suppository, or topical gel and generally comprise a base, carrier, or absorption-promoting agent adapted for intrarectal delivery.